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Abstract
Background: K13 propeller (k13) polymorphism are useful molecular markers for tracking the emergence and spread
of artemisinin resistance in Plasmodium falciparum. Polymorphisms are reported from Cambodia with rapid invasion
of the population and almost near fixation in south East Asia. The study describes single nucleotide polymorphisms in
Kelch protein propeller domain of P. falciparum associated with artemisinin resistance from Southern Pakistan.
Methods: Two hundred and forty-nine samples were collected from patients with microscopy confirmed P. falciparum malaria attending Aga Khan University Hospital during September 2015-April 2018. DNA was isolated using the
whole blood protocol for the QIAmp DNA Blood Kit. The k13 propeller gene (k13) was amplified using nested PCR.
Double-strand sequencing of PCR products was performed using Sanger sequencing methodology. Sequences were
analysed with MEGA 6 and Bio edit software to identify specific SNP combinations.
Results: All isolates analysed for k13 propeller allele were observed as wild-type in samples collected post implementation of ACT in Pakistan. C580Y, A675V, Y493H and R539T variants associated with reduced susceptibility to
artemisinin-based combination therapy (ACT) were not found. Low frequency of M476I and C469Y polymorphisms
was found, which is significantly associated with artemisinin resistance.
Conclusion: Low frequencies of both nonsynonymous and synonymous polymorphisms were observed in P. falciparum isolates circulating in Southern Pakistan. The absence of known molecular markers of artemisinin resistance
in this region is favourable for anti-malarial efficacy of ACT. Surveillance of anti-malarial drug resistance to detect its
emergence and spread need to be strengthened in Pakistan.
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Background
Drug resistance to anti-malarial is a major public health
problem in malaria endemic countries, even with reduction in malaria cases and deaths, it is estimated that 229
million cases of malaria occurred worldwide in 2019
leading to an estimated—409,000 deaths globally [1].
Despite the significant decline in malaria morbidity and
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mortality over 15 years (2000–2015), a total of 413,533
confirmed malaria cases were reported in 2019 out of
which 87,169 were confirmed Plasmodium falciparum
in Pakistan [1]. According to the World Health Organization (WHO), first-line recommended treatment in
Pakistan for uncomplicated P. falciparum malaria infections was artesunate plus sulfadoxine-pyrimethamine
(AS + SP) due to high prevalence of chloroquine resistance in P. falciparum isolates [2].
This treatment policy has been recently revised to
artemether-lumefantrine + primaquine for uncomplicated P. falciparum malaria [1]. Rapid emergence and
spread of artemisinin resistance in P. falciparum is however of great concern. Plasmodium falciparum resistance
to artemisinin is firmly established in five countries in the
Greater Mekong Sub region: Cambodia, Laos, Thailand,
Myanmar, and Vietnam [3, 4].
Spread of artemisinin resistance in P. falciparum
requires effective molecular surveillance of artemisinin
resistance. Recently, polymorphisms in the k-13 propeller gene in P. falciparum have been found to be a useful
marker for artemisinin resistance. Single nucleotide polymorphisms (SNPs) in the k13 region are associated with
delayed parasite clearance, both in vivo and in vitro and
significantly associated day 3 positive parasitaemia [3, 4].
More than 200 mutations in k13 gene, including 108 nonsynonymous variants have been reported globally [5].
Polymorphisms at nineteen loci in k13 propeller gene
(k13) reported from southeast Asia became a molecular signature of artemisinin resistance [6, 7]. Variants
at position F446I, N485Y, Y493H, R539T, P574L and
C580Y were responsible for delayed parasite clearance
in patients treated with artemisinin-based combination
therapy (ACT) and are, therefore, important determinants of artemisinin resistance [8, 9]. Further, genome
wide association studies (GWAS) confirmed that these
mutations demonstrate independent emergence at multiple geographical locations thus needs large-scale molecular surveillance [10, 11].
k13 SNPs associated with artemisinin resistance from
the China-Myanmar border, India, Bangladesh and some
African countries have been reported [4, 10, 12–14]. Various non-synonymous variants associated with delayed
parasite clearance have been reported from Africa in low
frequencies [5]. A578S is the most common non-synonymous mutation found in parasites from five countries
in sub-Saharan Africa, Western Kenya and Equatorial
Guinea [15]. A578S mutation was present with a prevalence of > 1% and located close to the C580Y mutation
[10].
There is a paucity of data on molecular markers of artemisinin resistance in P. falciparum from Pakistan. Therefore, rapid molecular surveillance of parasite populations
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for artemisnin resistance can help to inform the selection of drugs by control programmes. As an adjunct to
in vivo drug efficacy studies, large-scale molecular surveillance of drug resistance markers is needed urgently in
Pakistan. The aim of this study was to assess the genetic
polymorphisms in k13 propeller of P. falciparum associated with artemisinin resistance from Southern Pakistan.
Molecular data collected from malaria-endemic regions
will help in understanding the presence of variants in k13
propeller gene associated with delayed parasite clearance
in P. falciparum. The study reports k13 propeller SNPs
and Pfmdr1 gene copy number variation in P. falciparum malaria cases from Southern Pakistan.

Methods
Study setting, participants and ethics

The study was conducted between June 2015–2018 at the
Aga Khan University Hospital, a tertiary hospital located
in central Karachi, and its established chain of primary
health care and diagnostic service centers located in
Sindh and Baluchistan provinces, Pakistan. In the study
area, malaria transmission peaks during and after the
monsoon season that lasts from June to October. Patients
with microscopy confirmed P. falciparum mono-infection were eligible for enrolment irrespective of age, gender and disease severity.
The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice [16].
Informed consent was obtained from all participants or
in case of children from their parents/legal guardians.
The study was approved by the ethical review committee
of Aga Khan University Hospital, Karachi, Pakistan.
Blood collection and microscopy

Two ml of intravenous blood were collected in an EDTA
tube from all patients suspected of malaria referred to
the laboratory for investigation of malaria infection. For
screening purposes, a thick blood film was prepared and
analysed using Leishman stain according to routine laboratory practice. In case of a positive screening result, a
thick and thin Giemsa-stained blood film was prepared
for confirmation of the presence of malaria parasites and
species identification. For all patients with confirmed
P. falciparum mono-infection the parasite density was
assessed by counting asexual parasites against 200 white
blood cells (WBC) on the thick film and quantified
(parasites/µl) by assuming an average of 8000 WBC per
μl blood [17]. All blood slides were examined by experienced microscopist at the clinical laboratory of Aga Khan
University Hospital. For quality control, 10% of the blood
slides were re-examined by an independent microscopist
unaware of the initial result.
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The remaining blood was transferred to cryovials
and kept frozen at −80ºC until used for DNA extraction. A brief epidemiological and demographic history
was also collected from each participant using a structured questionnaire.
DNA extraction and PCR genotyping of k13 propeller
domain

DNA was extracted using Qiamp DNA mini Kits (Qiagen, USA) from 200 µl of whole blood as per manufacturer’s instructions. Extracted DNA was stored at
– 20 °C until amplified by PCR.
The k13 propeller domain was amplified by nested
PCR described elsewhere [4]. Briefly, using the following primers: for the primary PCR (kelch-out-f
5′CGGAGTG ACCA AATCTG GGA-3′ and kelch-out-r
5′GGGA ATC TGGTGGTAACAG C-3′) and the nested
PCR (kelch-in1-r 5′GCCT TGT TGA AAGAAG CA
GA-3′, kelch-in1-f 5′-GCCAAGC TGCCAT TCATT
TG-3′ kelch-in-f_5′CGCC AGC ATTGTTGAC TAAT-3′
and kelch-in-r 5′GCGGAAGTAGTAG CGAGAAT-3′).
The size of nested PCR products were 1312 and 849 bp
corresponding to nucleotide 101–1412 and 1279–2127
(representing codons 427–709) of PF3D7_1343700.
k13 propeller domain representing codons 427–709
included variants related to delayed parasite clearance. PCR products were resolved on 2% agarose gels
(Amresco, Solon, OH) visualized under UV transillumination (GelDoc®, Biorad, Hercules, CA, USA)
(Additional file 1).
Secondary PCR products were purified by ExoSAPIT (Affymetrix, Santa Clara, CA, USA) and sequenced
commercially (Macrogen Inc. Seoul, Korea). The primers for sequencing were same with those of nested
PCR.
Pfmdr1 gene copy number variation polymorphism
was determined using real time PCR (ABI Prism® 7500)
as previously described [18]. All samples were run in
duplicates. The clones, 3D7 and K1 were used as single
copy calibrators and FCB and Dd2 represented multiple
copy controls. Pfmdr1 copy numbers were calculated
using a comparative threshold method (ΔΔCt method).
Statistical analyses

Data were entered, validated and analysed using
SPSS version 16.0. Molecular Evolutionary Genetics Analysis (MEGA) software version 10 was used to
analyse the sequences using the 3D7 clone sequence
(PF3D7_1343700 K13) obtained from NCBI database
as a reference [19] (Additional file 2). SNP proportions were calculated as the number carrying a certain
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resistant allele divided by the number of samples with
positive PCR outcome.

Results
A total of 1016 patients with malaria were included
in this study and two hundred and forty-nine were
microscopy and PCR confirmed for P. falciparum
mono-infection, remaining were confirmed as P. vivax
malaria. Patients from all age groups were infected and
there was no significant difference among pediatrics
and adult population. The demographic of the patients
are presented in Table 1. A total of 241 (97%) sequence
from k13 propeller PCR products were obtained. K13
propeller gene sequences from study isolates were compared with the reference 3D7 strain (PF3D7_1343700)
retrieved from Gene bank.
Substitutions at positions Y493H, F446I, R539T,
R561H, P574L and C580Y were not detected in this
study isolates. M476I was observed in was observed
in 3 isolates none of the patients had history of travel
and recovered from malaria post treatment. C469Y was
observed in one isolate. Nonsynonymous novel mutations at positions T508N and S577L were observed in
12 (5%) and 13 (5%) isolates, respectively. These novel
mutations were associated with delayed parasite clearance or treatment failures in the study subject. Low
frequency of K189T mutation outside k13 propeller
region was reported in this study (Table 2). No k13
propeller validated variants were detected at positions
F446I, Y493H, G538V, R539T, P553L, R561H, V568G,
P574L, C580Y and A675V in this study. Double mutations were not observed in any isolate, all the samples
tested showed single k13 variant. The most common
k13 haplotype based on globally reported 19 SNPs was
wild type in this study. The wild type haplotype defined
Table 1 Demographic characteristics of enrolled patients
All
[n = 1016]

P.vivax
[n = 767]

P. falciparum
[n = 249]

Agea
68 [6.69%]

46 [5.99%]

22 [8.8%]

6–15 years

≤ 5 years

137 [13.4%]

97 [12.6%]

40 [16.0%]

> 15 years

811 [79.8%]

624 [81.3%]

187 [75.1%]

Sexa
Male

705 [69.3%]

529 [68.9%]

176 [70.6%]

Female

311 [30.6%]

238 [31.0%]

73 [29.3%]

12,720
[80–540000]

7480 [80–126000]

Parasite
11,100
densityb
[80–540000]
[parasites/µl]
a
b

Number of patients are presented with proportions in brackets

Parasite densities were available form 216 patients. Median data are presented
with range in brackets
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Table 2 Frequency of k13 propeller variants observed in this study
Variant types

Single nucleotide
polymorphism

Base substitution

Variant Frequency

Wild type

Status

Variant type

Wild type

–

–

–

241 (1)

–

WT

K189T

c.566A > C

AAA > ACA

1 [0.004]

240 [0.99]

–

NS

C469Y

c.1407C > G

TGC > TGG

1 [0.004]

240 [0.99]

Candidate

NS

M476I

c.1428G > T

ATG > ATT

3 [0.01]

238 [ 0.98]

Validated

NS

F483I

c.1447T > A

TTT > ATT

9 [0.04]

232 [0.96]

–

NS

S485N

c.1454G > A

AGT > AAT

7 [0.03]

234 [0.97]

–

NS

F491F

c.1473F > F

TTC > TTT

52 [0.22]

189 [0.78]

–

S

L492L

c.1476A > G

TTA > TTG

2 [0.01]

239 [0.99]

–

S

F506V

c.1516 T > G

TTT > GTT

8 [0.03]

232 [0.96]

–

NS

T508N

c.1523C > A

ACT > AAT

12 [0.05]

229 [0.95]

–

NS

S577L

c.1730S > L

TCA > TTA

13 [0.05]

228 [0.95]

–

NS

NS nonsynonymous, S synonymous, [–] variants of unknown significance or not reported
k13 variants that are either validated or are associated/candidates for ART resistance are shown

as FGNSCAFLYGPEPACVEAA at amino acid positions 446, 450, 458, 459, 469, 481, 483, 492, 519, 533,
556, 574, 578, 580, 581, 668, 675 and 676. Amplification
in pfmdr1 gene copy number was not observed in the
study isolates.

Discussion
This study reports survey of k13 propeller polymorphisms in P. falciparum from southern Pakistan majority of samples were from metropolitan of Karachi with a
population of more than 16 million. Candidate variants
in the k13 gene N458Y, F466I, Y493H, R539T, P574L
and C580Y, which were associated with delayed parasite clearance and prolonged ex vivo parasite survival in
Southeast Asia were not observed [4, 8].
K189T is a common mutation observed in upstream
region of k13 gene. It has not been associated with artemisnin resistant clinical phenotype [14, 20]. Low proportion of K189T was found in this study. Low frequencies
of K189T has also been reported from Bangladesh and
China-Myanmar border in comparison to a higher
prevalence in Africa. In addition, K189T mutation was
reported from India with a comparatively higher frequency, however no correlation with artemisnin resistance was observed [21].
Low frequency of M476I with no clinical evidence of
artemisnin resistance was observed in this study. M476I
variant has been associated with artemisinin tolerance
in vitro in the Tanzanian parasite population and is a
validated marker of artemisinin resistance. This finding
is alarming and suggest that larger scale monitoring may
be urgently required. These variants in k13 gene have also
previously been reported from southern Myanmar, South
Vietnam, Bangladesh and India [14, 22]. C469Y is known

to be associated with artemisinin tolerance from ChinaMyanmar border and Uganda is reported in one isolate in
this study [3, 23].
Variants associated with artemisnin resistance in South
East Asia were not detected in Africa suggesting independent origin of mutation in different regions [10, 24,
25]. V566I and A578S are most notable of seven unique
nonsynonymous variants reported from sub-Saharan
Africa which were not observed in Southeast Asia [26].
A578S has been commonly reported from Africa, India
and Bangladesh with no clinical evidence of artemisinin
resistance [5, 21].
F466I, Y493H, R539T, P574L and C580Y variants have
reached intermediate to fixation status in South East Asia
and China where currently artemisinin resistance is confined. These variants confer resistance in an artemisininresistant parasite line selected in the laboratory and are
associated with delayed parasite clearance in clinical
isolates [4, 27]. F446I which is highly prevalent in ChinaMyanmar and Northern Myanmar and has been associated with prolonged parasite clearance recently was not
reported in this study [28, 29]. C580Y is highly prevalent
in Cambodia, Thailand and Myanmar. The frequency
of the C580Y allele increased significantly in two western provinces of Cambodia and it became near fixation
in these areas. Association of N458Y with artemisinin
resistance was inconsistently reported from the ThaiMyanmar border region. Y493H and C580Yvariants
reportedly originating from Cambodia have subsequently
spread throughout Vietnam [6].
Single nucleotide polymorphism in k13 conferring
drug resistance have emerged independently and differ
regionally [4, 10]. In recent study it has been noted that
validated and candidate k13 mutation may not confer
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artemisinin resistance in isolation but would act in presence of multiple variant which were noted in African and
Southeast Asian parasite populations [27, 30].
In this study, low frequency of k13 propeller mutations were observed and no previously validated artemisinin resistance variant reported from South East Asia
were found. A majority of isolates in this study carried
wild-type k13 propeller gene corresponds to haplotype
FGNSCAFLYGPEPA-CVEAA [31]. Synonymous and
nonsynonymous substitutions of unclear phenotype were
identified. Recent studies from Pakistan also reported a
lack of k13 variants associated with artemisinin resistance. Both studies, however reported synonymous and
non- synonymous with no or limited association with
artemisnin resistance consistent with current findings
[32, 33]. These results are encouraging and suggest that
artemisinin resistance is not yet established in Southern
Pakistan. However, presence of low frequency of M476I
and evolving variants is however alarming. This study
shows there may be regional variation in mutation profile
and therefore it is important that consistent and regular
molecular surveillance monitoring is conducted throughout Pakistan.
Although critical SNPs associated with artemisinin
resistance in SE Asia were not detected in this study and
concur with African studies which report different mutation [24, 25]. Novel k13 propeller coding substitutions
T508N and S57L were reported in this study. The phenotypes of these coding polymorphisms remain unclear
and will require further characterization to better characterize the clinical impact on artemisinin resistance in
Southern Pakistan.
This study confirms that recently revised treatment
option from AT + SP to AL for uncomplicated P. falciparum malaria should be an effective regimen as pfmdr1
gene amplifications were not observed. Pfmdr1 gene
copy number amplification has been associated with
an increased risk for treatment failure after mefloquine
monotherapy and artesunate-mefloquine combination
therapy [18]. Presence of single copy pfmdr 1 gene is
consistent with previously reported studies from Pakistan [2]. The low prevalence of pfmdr1 amplifications
observed in this study suggests that both artesunatemefloquine and artemether-lumefantrine combination
would be efficacious in Southern Pakistan.
One of the limitation of the present study was absence
of availability of coordinated clinical follow up, patient
outcomes and molecular data to provide better understanding of the biological and clinical impact of these
unique genotypes. Complementing these studies with
ongoing, large-scale molecular epidemiologic surveillance will enhance ability to monitor artemisinin
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resistance in Pakistan. Integration of these efforts in the
national malaria control programme may help forestall
the spread of resistance and enhance the global durability
of artemisinin therapies.
The absence of known molecular markers of artemisinin resistance in this region is favourable for the
anti-malarial efficacy of ACT. However, presence of
M476I in low frequency is matter of concern in Pakistan. It is difficult to predict how soon resistance variants may appear in absence of wide scale molecular
surveillance. Validated data on k13 mutation are known
to have population based specificity therefore data
from Pakistan has critical implications for implementation of appropriate treatment policy and development
of elimination strategy. Molecular surveillance can provide a framework to rapidly monitor for the emergence
or importation of resistance alleles.
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